MENU
+Compare
RLMD
Stock ticker: NASDAQ
AS OF
Nov 13, 04:59 PM (EDT)
Price
$3.89
Change
-$0.02 (-0.51%)
Capitalization
286.73M

RLMD Relmada Therapeutics Forecast, Technical & Fundamental Analysis

Relmada Therapeutics Inc is a clinical-stage biotechnology company... Show more

RLMD
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for RLMD with price predictions
Nov 12, 2025

RLMD in +29.90% Uptrend, advancing for three consecutive days on November 12, 2025

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where RLMD advanced for three days, in of 287 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 04, 2025. You may want to consider a long position or call options on RLMD as a result. In of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for RLMD just turned positive on November 04, 2025. Looking at past instances where RLMD's MACD turned positive, the stock continued to rise in of 38 cases over the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 217 cases where RLMD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RLMD declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

RLMD broke above its upper Bollinger Band on November 10, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. RLMD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.986) is normal, around the industry mean (24.439). P/E Ratio (0.000) is within average values for comparable stocks, (63.753). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.001). Dividend Yield (0.000) settles around the average of (0.046) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (322.723).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RLMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
RLMD
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

RLMD is expected to report earnings to rise 50.00% to -44 cents per share on November 13

Relmada Therapeutics RLMD Stock Earnings Reports
Q3'25
Est.
$-0.45
Q2'25
Beat
by $0.10
Q1'25
Missed
by $0.21
Q4'24
Beat
by $0.09
Q3'24
Missed
by $0.04
The last earnings report on August 07 showed earnings per share of -30 cents, beating the estimate of -40 cents. With 670.04K shares outstanding, the current market capitalization sits at 286.73M.
A.I. Advisor
published General Information

General Information

a clinical-stage biotechnology company, which engages in the development of d-methadone receptor antagonist, which is a chemical entity that addresses areas of high unmet medical need in the treatment of central nervous system diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
2222 Ponce de Leon Boulevard
Phone
+1 786 629-1376
Employees
20
Web
https://www.relmada.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BSXGF0.25N/A
+0.49%
Belo Sun Mining Corp.
ADRZF69.89N/A
N/A
Andritz AG
LTOUF44.00N/A
N/A
Larsen & Toubro Ltd.
EXALF90.00N/A
N/A
EXAIL TECHNOLOGIES
ZEOX1.86-0.06
-2.99%
Zeo ScientifiX Inc.

RLMD and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, RLMD has been loosely correlated with SYRE. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if RLMD jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RLMD
1D Price
Change %
RLMD100%
+18.84%
SYRE - RLMD
36%
Loosely correlated
+0.34%
ENTO - RLMD
36%
Loosely correlated
+3.22%
PRTC - RLMD
31%
Poorly correlated
+2.82%
AVXL - RLMD
31%
Poorly correlated
+0.73%
ZVRA - RLMD
29%
Poorly correlated
-0.32%
More